Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Brelovitug · BJT-778, BTG

Other · developed by Mirum Pharmaceuticals

Phase 2/3 Most advanced trial

MIRM Developer

2 Registered trials

What is Brelovitug?

Brelovitug is an investigational drug studied in Chronic Hepatitis D Infection, Chronic Hepatitis D.

At a glance

Also known as: BJT-778, BTG
Drug type: Other
Therapy area: Infectious disease
Developer: Mirum Pharmaceuticals, Inc. (MIRM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: 4M5NX28KQZ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07454837	Phase 2/3	Chronic Hepatitis D	Recruiting	MIRM
NCT06907290	Phase 2/3	Chronic Hepatitis D Infection	Active not recruiting	MIRM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis DChronic Hepatitis D Infection

More from Mirum Pharmaceuticals

Cholic Acid FDA approved Maralixibat FDA approved MRM-3379 Phase 2 Volixibat Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MIRM page.

Follow MIRM, the company behind Brelovitug

See MIRM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MIRM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z